1. Scrip
  2. >>Therapy Areas

AZ's Lynparza Shines Again In Prostate Cancer Study

PARP Inhibitor Improves Overall Survival

 
• By Kevin Grogan

With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.

Jigsaw_Pieces
If approved, prostate cancer would be the fourth indication for Lynparza • Source: Shutterstock

AstraZeneca PLC has revealed data showing that Lynparza is the first PARP inhibitor to improve overall survival (OS) in patients with advanced prostate cancer, the fourth indication for which the Merck & Co. Inc.-partnered blockbuster is expected to get approval in the coming weeks.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas